UCLA Turns Cord Blood Into Off-the-Shelf Cancer T Cells — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- UCLA researchers developed AlloESO-T cells from cord blood stem cells engineered with a receptor targeting NY-ESO-1, a protein present in many solid tumors including ovarian cancer and melanoma
- The AlloESO-T cells carry two detection systems — an engineered TCR plus natural killer cell receptors that recognize tumor stress signals — providing a backup route against antigen escape when cancer cells stop displaying NY-ESO-1
- In mouse models of ovarian cancer and melanoma, a single dose of AlloESO-T cells produced lasting tumor control and extended survival without graft-versus-host disease, while conventional donor T cells achieved only partial control and triggered the dangerous complication
- After one infusion, AlloESO-T cells expanded roughly 100-fold, infiltrated tumors, and remained active for weeks while mostly avoiding healthy organs — whereas conventionally engineered donor T cells accumulated in the liver and lungs and caused the toxicity the new strategy is designed to prevent
- From a small number of cord blood stem cells, researchers can generate trillions of therapeutic cells — enough for thousands of doses — within about six weeks, at an estimated $5,000 per dose versus hundreds of thousands of dollars for today's personalized treatments
- Co-senior author Lili Yang's lab has partnered with the UCLA Health Center for Advanced Biotherapies to manufacture clinical-grade cells for its CAR-NKT platform and expects to use the same manufacturing relationship to scale up AlloESO-T toward clinical testing
- The AlloESO-T cells have so far been evaluated only in preclinical mouse experiments and have not been tested in humans or approved by the FDA as safe or effective for human use
Why it matters: Personalized T-cell therapies can cost hundreds of thousands of dollars and take weeks to produce per patient. UCLA's cord-blood-derived AlloESO-T platform cuts estimated costs to $5,000 per dose while generating thousands of doses from a single starting supply — though the cells have only cleared mouse studies, meaning real-world savings depend on clinical trials that have not yet begun.
Ask SkimNews
